Comparison of MIBG and pentetreotide scintigraphy in children with neuroblastoma. Is the expression of somatostatin receptors a prognostic factor?

Anticancer Research

Volumn 17, Issue 3 B, 1997, Pages 1583-1588

  Kropp, Joachim ^a,c   Hofmann, Michael ^b   Bihl, Heiner ^b  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b KATHARINENHOSPITAL   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

MIBG; Neuroblastoma; Pentetreotide; Prognostic factor; Somatostatin receptor

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 125; CATECHOLAMINE; INDIUM 111; PENTETREOTIDE; SOMATOSTATIN RECEPTOR;

ARTICLE; CANCER RECURRENCE; CANCER REGRESSION; CATECHOLAMINE RELEASE; CHILDHOOD CANCER; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DRUG UPTAKE; FEMALE; HUMAN; INTERMETHOD COMPARISON; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROBLASTOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD; SCINTIGRAPHY; ULTRASOUND;

3-IODOBENZYLGUANIDINE; ADULT; CATECHOLAMINES; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FALSE NEGATIVE REACTIONS; FOLLOW-UP STUDIES; HUMANS; INDIUM RADIOISOTOPES; INFANT; IODINE RADIOISOTOPES; IODOBENZENES; NEOPLASM STAGING; NEUROBLASTOMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTORS, SOMATOSTATIN; REPRODUCIBILITY OF RESULTS; SOMATOSTATIN; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030989624     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Michaelis J, Kaatsch P: Cooperative documentation of childhood malignancies in the FRG. System design and five-year results. Monogr Paediatr 18: 56-62, 1986
2. Berthold FO: Biology of neuroblastoma. In: Neuroblastoma: tumor biology and therapy (Pochedly C, ed). Boca Raton, CRC Press Inc, 1990, pp 2-27.
3. Brodeur G: Molecular biology. In: Neuroblastoma: tumor biology and therapy (Pochedly C, ed). Boca Raton, CRC Press Inc, 1990, pp 31-
4. Look AT, Hayes FA, Shuster JJ, et al: Clinical relevance of tumor cell ploidy and N-myc gene amplifiication in childhood neuroblastoma: A pediatric oncology group study. J Clin Oncol 9: 581-591, 1991.
5. Hughes M, Marsden HB, Palmer MK: Histologic patterns of neuroblastoma related to prognosis and clinical staging. Cancer 34: 1706-1711, 1974.
6. Sty JR Wells RG: Radiographic imaging of neuroblastoma. In. Neuroblastoma: tumor biology and therapy (Pochedly C, ed). Boca Raton, CRC Press Inc, 1990, pp 147-170.
7. Gordon I, Peters AM, Gutman A: Skeletal assessment in neuroblastoma - the pitfalls of iodine- 123-MIBG scans. J Nucl Med 31:129-134, 1990
8. Bishop AE, Power RF, Polak JM: Markers for neuroendocrine differentiation. Path Res Pract 183: 119-128, 1988
9. Lamberts SWJ, Krenning EP, Reubi JC: The role of somatostatin and its analogs in the diagnosis and reatment of tumors. Endocr Rev 12: 450-482, 1991.
10. Krenning EP, Kwekkeboom DJ, Bakker WH et al: Somatostain receptor scmtigraphy with [111 In-DTPA-D-Phe1]-and[123I-Tyr3]octreotide: the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 20: 716-731, 1993.
11. Dörr U, Frank-Raue K, Raue F et al: The potential value of somatostation receptor scintigraphy in medullary thyroid carcinoma. Nucl Med. Commun 14: 439-445, 1993.
12. Kwekkeboom, DJ, v. Urk H, Pauw BKH et al. Octreotide scintigraphy for the detection of paragangliomas. J Nucl Med 34: 873-878, 1993.
13. Maggi M, Baldi E, Lanzilloti R, et al: Somatostatin receptors in human neuroblastoma cells. Chron Derm 2/3: 438-439, 1992.
14. Moertel CL, Reubi JC, Scheithauer B, Schaid DJ, Kyols LK: Somatostatin receptors (SS-R) are expressed and prelate with prognosis in childhood neuroblastoma. Pediatr Res 27: 146(A), 1990.
15. Qualman SJ, OæDorisio MS, Fleshman DJ, Shimada H, OæDorisio TM- Neuroblastoma: correlation of neuropeptide expression in tumor tissue with other prognostic factors. Cancer 70: 2005-2012 1992
16. Evans AE, DæAngio GJ, Rudolph J: Proposed staging for children with neuroblastoma. Cancer 27: 374-380, 1971.
17. Lamberts SWJ, Krenning EP, Klijn JGM, Reubi JC: The clinical use of somatostatin analogues in the treatment of cancer. Bailheres Clin Endocrinology and Metab 4: 29-50, 1990.
18. Busse E, Bartsch O, Kornhuber B: Research on the differentiation of human and murine neuroblastoma cells. Oncology 48: 196-201, 1991
19. Krenning EP, Bakker WH, Kooij PPM, et al: Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-Octreotid in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3Octreotid. J Nucl Med 33: 652-658, 1992.
20. Adrian HJ, Dör U, Bach D, Bihl H: Biodistributiion of 111Inpentetreotide and dosimetric considerations with respect to somatostatin receptor expressing tumor burden. Horm Metab Res 27 (Suppl 2): 18-23, 1993.
21. Kogner P, Björk O, Dominici C, Hedborg F, Theodorsson E: Vasoactive intestinal peptide (VIP) and somatostatin in childhood ganglioneuromas and neuroblastomas. Proc ASCO 11: 371 (A), 1992.
22. Moyes JSE, Babich JW, Carter R, Meller ST, Agrawal M, McElwain TJ- Quantitative study of radioiodinated metaiodobenzylguanidine uptake in children with neuroblastoma: correlation with tumor histopathology. J Nucl Med 30: 474-480, 1989.